文献速递产科母胎医学

胎儿和新生儿溶血性疾病:胎儿RHD基因分型、靶向预防及产前治疗

Hemolytic Disease of the Fetus and Newborn: Fetal RHD Genotyping, Targeted Prophylaxis, and Prenatal Therapies.
PubMed 文献 · Prenat Diagn · 2025-09-19

本文综述胎儿和新生儿溶血性疾病(HDFN)的产前管理,重点讨论无创胎儿RHD基因分型用于靶向产前预防、大脑中动脉收缩期峰值流速(MCA-PSV)检测胎儿贫血、宫内输血(IUT)及静脉注射免疫球蛋白(IVIG)等治疗,并提及阻断新生儿Fc受体(FcRn)的单克隆抗体作为有前景的替代方案。

要点

  • 无创胎儿RHD基因分型作为筛查工具可实现靶向产前预防,已在多个欧洲国家实施。
  • MCA-PSV多普勒超声是检测胎儿贫血的金标准,但宫内输血后的可靠性仍存争议。
  • IUT是严重胎儿贫血的主要治疗,但为有创操作且存在固有风险,尤其在妊娠早期。

核心结论

  • 抗D预防项目虽成功,但D同种免疫仍会发生,解决这些差距对确保最佳孕产妇护理至关重要。
  • 阻断FcRn的单克隆抗体可减少IgG再循环和胎盘转运,有望延迟或避免IUT需求。

研究设计与样本

  • 综述,概述现代产科护理中胎儿RHD基因分型及高质量医疗环境下HDFN的产前监测与治疗策略。

主要发现

  • 无创胎儿RHD基因分型作为筛查工具可实现靶向产前预防,已在多个欧洲国家实施。
  • MCA-PSV是检测胎儿贫血的金标准,但宫内输血后的可靠性仍存争议。
  • IVIG作为治疗手段已被提出,但疗效仍不确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemolytic disease of the fetus and newborn (HDFN) remains a significant concern in prenatal care primarily caused by maternal alloimmunization against fetal red blood cell antigens, most commonly the D antigen. Noninvasive fetal RHD genotyping, used as a screening tool, enables targeted antenatal prophylaxis and has been implemented in several European countries. Despite the success of anti-D prophylaxis programs, D alloimmunization still occurs and addressing these gaps is essential to ensure optimal maternal care. In pregnancies affected by HDFN, Doppler ultrasound assessment of middle cerebral artery peak systolic velocity (MCA-PSV) is the gold standard for detecting fetal anemia, though its reliability following intrauterine blood transfusion (IUT) remains debated. IUT is the primary treatment for severe fetal anemia; however, it remains an invasive procedure with inherent risks, particularly when performed early in pregnancy. Intravenous immunoglobulin (IVIG) has been proposed as a treatment, though its efficacy remains inconclusive. A promising alternative involves monoclonal antibodies blocking the neonatal Fc receptor (FcRn), reducing IgG recycling and placental transfer-with the potential to delay or obviate the need for IUT. This review provides an overview of fetal RHD genotyping in modern obstetric care and discusses prenatal monitoring and treatment strategies for HDFN within high-quality healthcare settings.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Thorup E, Thorsen S, Dziegiel MH, et al. Hemolytic Disease of the Fetus and Newborn: Fetal RHD Genotyping, Targeted Prophylaxis, and Prenatal Therapies. Prenat Diagn. 2025. PMID: 40973699. doi:10.1002/pd.6891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。